Therapeutically active compounds and their methods of use
US-2017044139-A1 · Feb 16, 2017 · US
Methods of treatment of malignancies
US10188656B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10188656-B2 |
| Application number | US-201615368439-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 2, 2016 |
| Priority date | Dec 4, 2015 |
| Publication date | Jan 29, 2019 |
| Grant date | Jan 29, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating acute myeloid leukemia in a subject comprising administering to the subject a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-[2-(trifluoromethyl)pyridin-4-yl]amino-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein the acute myeloid leukemia is characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of NRAS. 2. The method of claim 1 , wherein the mutant allele of IDH2 is IDH2 R140Q or R172K. 3. The method of claim 1 , wherein the acute myelogenous leukemia is relapsed or refractory acute myelogenous leukemia, characterized by the presence of a mutant allele of IDH2. 4. The method of claim 1 , wherein 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt, solvate or tautomer thereof is administered in a dose of about 20 to 2000 mg/day. 5. The method of claim 4 , wherein 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt, solvate or tautomer thereof is administered in a dose of about 50 to 500 mg/day. 6. The method of claim 1 , wherein the subject has 3 or less co-occuring mutations. 7. The method of claim 1 , wherein the mutant isocitrate dehydrogenase 2 (IDH2) inhibitor is 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol. 8. The method of claim 1 , wherein the mutant isocitrate dehydrogenase 2 (IDH2) inhibitor is a mesylate salt of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10188656B2 cover?
- Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
- Who is the assignee on this patent?
- Agios Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/53. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).